the worse survival in patients with lymph node metastasis, TNM stage III as well as nuclear grade G3 tumors

cells, such as inhibition of cell proliferation, colony formation, migration, invasion and xenograft tumor

interactions among neuropeptides, receptor isoform-specific signaling events, and the inflammatory microenvironment

Glioma is the most common adult malignant brain tumor and requires novel therapeutic strategies to improve

Insights into GPCR Function Synergistic and Competitive Lipid Interactions in the Serotonin 1A Receptor Microenvironment

GPCRs in Oncology and Immunology G protein-coupled receptor-mediated signaling of immunomodulation in tumor

Convergent substitutions and recurrent gene loss in sauropsids Noval insights and therapeutic strategies for tumor-induced

under suboptimal conditions Exploiting frequent and specific expression of PRL3 in pediatric solid tumors

Grants Under Nasdaq Listing Rule 5635(c)(4) GPCR signaling contributes to immune characteristics of the microenvironment

disease GPCRs in Oncology and Immunology Aberrant hormone receptors regulate a wide spectrum of endocrine tumors

death by 72% as first-line treatment for patients with advanced gastroenteropancreatic neuroendocrine tumors

A2aR on lung adenocarcinoma cells: A novel target for cancer therapy via recruiting and regulating tumor-associated

Palmitoylation of the Glucagon-like Peptide-1 Receptor Modulates Cholesterol Interactions at the Receptor-Lipid Microenvironment

GPR68-ATF4 signaling is a novel prosurvival pathway in glioblastoma activated by acidic extracellular microenvironment

GPCRomics: GPCR Expression in Cancer Cells and Tumors Identifies New, Potential Biomarkers and Therapeutic

scavenging of canonical chemokine receptors Clearing circulating chemokines and chemokines from tissue microenvironments

Glioblastoma multiforme (GBM) is the most common and aggressive primary brain tumour in adults. this, the prognosis remains poor, with an impacted quality of life during treatment coupled with brain tumour

However, β-arrestins do not consistently act as oncogenes or tumor suppressors.

investigation and may enable further stratification of the ability of kisspeptin to influence breast tumour

First Patient Enrolled in Phase 1/2 “ELUCIDATE” Trial Assessing GTAEXS617 in Advanced Solid Tumours A

metabolic steatotic liver disease GPCRs in Oncology and Immunology Chemoattractant receptor signaling in humoral

neuroprotective and neurogenic properties GPCRs in Oncology and Immunology Chemoattractant receptor signaling in humoral